Evaluation of the Effects of a Technologically-Enhanced Personal Coaching Program on Hemoglobin A1c in Type 2 Diabetics
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diabetes Mellitus
- Sponsor
- Welkin Health
- Enrollment
- 72
- Locations
- 1
- Primary Endpoint
- Change in Hemoglobin A1c
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Participants diagnosed with Type 2 diabetes receive personal coaching from a Certified Diabetic Educator (CDE) over a six-month period. The coaching program is enhanced using an mobile application and care management platform.
Detailed Description
Participants diagnosed with Type 2 diabetes receive personal coaching from a Certified Diabetic Educator (CDE) over a six-month period. The coaching program is enhanced by integrating a participant-facing mobile application with the coaching platform. Blood glucose test results automatically populate the coaching platform, providing the CDE with information that may better support their coaching efforts. The participants complete Diabetes Self Management Education (DSME) learning modules for the first 7-12 weeks. Following completion of the modules, the coach continues to provide support to the participant until 24 weeks after the participant's enrollment.
Investigators
Kristin Neland
Clinical Program Designer
Welkin Health
Eligibility Criteria
Inclusion Criteria
- •Lives in the United States
- •Speaks and understands English
- •Has a Type 2 diabetes mellitus diagnosis
- •Has a LifeScan Verio Flex blood glucose meter, which is connected to OneTouch Reveal ® app
- •Has a verified A1c ≥ 8%
- •Willing to participate in coaching program
Exclusion Criteria
- •Uses a continuous glucose monitoring device
- •Currently pregnant
- •Unable to make lifestyle behavioral changes due to a cognitive or physical disability
- •Has end stage renal disease (ESRD) diagnosis
- •Is not able to read or understand English
Outcomes
Primary Outcomes
Change in Hemoglobin A1c
Time Frame: A1c measured at baseline, at 12 weeks since study enrollment, and at 24 weeks since enrollment, which marks the participant's completion of the study
Blood serum test to measure glucose control